Pharma BD Deal Intelligence
Chai Discovery announced a collaboration with GSK following a successful technology evaluation in which GSK ran internal wet-lab testing of Chai-generated designs against GSK targets, zero-shot and without target-specific training; GSK reported finding binders to all targets tested, which led to expansion into a broader collaboration. Under the agreement GSK gains access to Chai's platform, including its protein-folding and molecular-design models, to power discovery programs across its pipeline. Financial terms were not disclosed. The agreement is Chai Discovery's sixth pharma deal in nine months, joining prior agreements with Eli Lilly, Pfizer, Novartis, argenx and Bristol Myers Squibb.
← Browse all deals · How we score deals
More: 2026 deals · GSK plc deals